Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.270
-0.080 (-5.93%)
At close: Jan 21, 2025, 4:00 PM
1.320
+0.050 (3.94%)
Pre-market: Jan 22, 2025, 6:42 AM EST
Dermata Therapeutics Employees
Dermata Therapeutics had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,408,812
Market Cap
2.59M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 1 | 14.29% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
DRMA News
- 22 hours ago - Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R) - Accesswire
- 5 weeks ago - Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) - Accesswire
- 6 weeks ago - Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - Accesswire
- 7 weeks ago - Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - Accesswire
- 2 months ago - Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Accesswire
- 2 months ago - Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024 - GlobeNewsWire
- 3 months ago - Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 - Accesswire
- 4 months ago - Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Accesswire